Pfizer’s breast cancer drug meets primary endpoint

April 16, 2015 9:50 AM

17 0

The clinical trial of the Pfizer’s breast cancer drug was halted due to some problems relating to the performance of the drug, but now the problems have been solved and now the drug is ready for clinical trial.

The decision to halt the study was based on an assessment by an independent data-monitoring committee.

Read more

To category page